{"id":6112,"date":"2019-10-04T16:48:13","date_gmt":"2019-10-04T11:18:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6112"},"modified":"2022-08-16T09:56:11","modified_gmt":"2022-08-16T04:26:11","slug":"palforzia-for-peanut-allergy","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy","title":{"rendered":"FDA is reviewing a dangerous way to treat Peanut Allergy"},"content":{"rendered":"\n

Peanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage.  
The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalent population of Peanut Allergy (PA) in the 7 major markets was estimated to be around from approximately 6,754 cases in 2016. <\/p>\n\n\n\n

According to DelveInsight\u2019s analysis, Peanut allergy is more dominant in male children and the case reverses when it comes to the adult population, i.e., Preponderance of Peanut allergy is more in adult females. <\/p>\n\n\n\n

Yet, there is no standard cure for it. But it might change now. <\/strong><\/p>\n\n\n\n

FDA committee\u2019s nod to AR101<\/strong><\/h4>\n\n\n\n

Last month, FDA experts recommended a unique yet dangerous way to tame the Peanut allergy<\/a>. The approval of Palforzia (AR101), a peanut powder, is designed in a way to reduce the intensity of the peanut allergy in the person with time. <\/p>\n\n\n\n

Developed by Aimmune Therapeutics,\nthe therapy is suitable to be used in patients of age ranging from 4 to 17 as a\npart of oral immunotherapy protocol. <\/p>\n\n\n\n

The therapy works by exposing the children to peanuts in controlled dosages. The aim of the therapy is to increase the tolerance of the allergic person, which is in contrary to the existing treatment options which advice to avoid the allergic substance at all costs. <\/p>\n\n\n\n

The committee\u2019s decision did face some serious criticism as this might result in the occurrence of serious allergic reactions. However, the concern for safety was always in the picture. The experts said the treatment option is good to go based on the results of the trials so far while keeping a dose of injectable epinephrine handy for additional safety. <\/p>\n\n\n\n

The committee\u2019s vote in favour of the treatment marks the landmark in the field of Peanut allergy treatment landscape. <\/a>This innovative way to make the immune system tolerant to allergy by administering the calibrated doses has given hopes to several allergic people. The doctors and peanut allergy patient pool are now waiting for the designated capsules containing consistent peanut proteins. <\/p>\n\n\n\n

The National Institute of Allergy\nand Infectious Disease (NIAID) has reported that approximately one in 90 people\nin the United States, or 1.1%, have a tree nut and\/or peanut allergy. <\/p>\n\n\n\n

Peanut Allergy Market<\/strong><\/h4>\n\n\n\n

According to DelveInsight, the Peanut Allergy market size <\/a>in the seven major markets is expected to increase by 2027 from USD 5,086 million in 2016. <\/p>\n\n\n\n

The United States accounts for\nthe largest market size of PA in comparison with the EU5 (the United Kingdom,\nGermany, Italy, France, and Spain) and Japan. In 2016, the US market for Peanut\nAllergy was around USD 3,213 million, which is estimated to by 2027.<\/p>\n\n\n\n

With no cure at hand, the Peanut allergy treatment landscape, presently, is dominated by off-label therapies. <\/strong><\/p>\n\n\n\n

DelveInsight has performed detailed historical market analysis for Peanut Allergy. Currently, the market comprises of symptomatic medications for Peanut Allergy such as epinephrine, antihistamines and other anti-allergens. Epinephrine is the first line of treatment of treating severe and fatal allergic reactions and anaphylaxis. Anti-histamines and other anti-allergic medications are generally used in patients with mild-to-moderate peanut allergy reactions. Additionally, probiotics and dietary changes are also employed for treating and avoiding Peanut Allergy.<\/p>\n\n\n\n

Other key pharma players, Prota Therapeutics, AnaptysBio, and Genentech are involved in developing therapies for Peanut Allergic. The launch of emerging therapies, Viaskin Peanut (DBV Technologies), PPOIT (Prota Therapeutics), ANB020 (AnaptysBio), Omalizumab (Genentech) etc. will significantly impact the Peanut Allergic market d<\/a>uring the study period (2016-2027).<\/p>\n","protected":false},"excerpt":{"rendered":"

Peanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage.  The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalent population of Peanut Allergy […]<\/p>\n","protected":false},"author":1,"featured_media":6113,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[1873,704,1135,6428,2193,17793,17794,17792],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-6112","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-anaptysbio","tag-fda","tag-genentech","tag-palforzia","tag-peanut-allergy","tag-peanut-allergy-market","tag-peanut-allergy-pipeline","tag-prota-therapeutics","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"\nFDA is reviewing a dangerous way to treat Peanut Allergy - DelveInsight<\/title>\n<meta name=\"description\" content=\"FDA experts' approval of Palforzia (AR101), a peanut powder, is designed in a way to reduce the intensity of the peanut allergy in the person with time.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA is reviewing a dangerous way to treat Peanut Allergy - DelveInsight\" \/>\n<meta property=\"og:description\" content=\"FDA experts' approval of Palforzia (AR101), a peanut powder, is designed in a way to reduce the intensity of the peanut allergy in the person with time.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-04T11:18:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-16T04:26:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/fda.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA is reviewing a dangerous way to treat Peanut Allergy - DelveInsight","description":"FDA experts' approval of Palforzia (AR101), a peanut powder, is designed in a way to reduce the intensity of the peanut allergy in the person with time.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy","og_locale":"en_US","og_type":"article","og_title":"FDA is reviewing a dangerous way to treat Peanut Allergy - DelveInsight","og_description":"FDA experts' approval of Palforzia (AR101), a peanut powder, is designed in a way to reduce the intensity of the peanut allergy in the person with time.","og_url":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-04T11:18:13+00:00","article_modified_time":"2022-08-16T04:26:11+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/fda.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy","url":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy","name":"FDA is reviewing a dangerous way to treat Peanut Allergy - DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/fda.jpg","datePublished":"2019-10-04T11:18:13+00:00","dateModified":"2022-08-16T04:26:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA experts' approval of Palforzia (AR101), a peanut powder, is designed in a way to reduce the intensity of the peanut allergy in the person with time.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/palforzia-for-peanut-allergy#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/fda.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/fda.jpg","width":772,"height":482,"caption":"Peanut allergy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/fda-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">AnaptysBio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Palforzia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">peanut allergy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Peanut Allergy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Peanut Allergy Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Prota Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AnaptysBio<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">Palforzia<\/span>","<span class=\"advgb-post-tax-term\">peanut allergy<\/span>","<span class=\"advgb-post-tax-term\">Peanut Allergy Market<\/span>","<span class=\"advgb-post-tax-term\">Peanut Allergy Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Prota Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Oct 4, 2019","modified":"Updated on Aug 16, 2022"},"absolute_dates_time":{"created":"Posted on Oct 4, 2019 4:48 pm","modified":"Updated on Aug 16, 2022 9:56 am"},"featured_img_caption":"Peanut allergy ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6112"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6112\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6113"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6112"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6112"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}